Cited by 232Protein Degradation and InhibitorsChemical Synthesis and AnalysisUbiquitin and proteasome pathways

Impact of linker length on the activity of PROTACs

Open access
Cyrus, Kedra, Wehenkel, Marie, Choi, Eun-Young, Han, Hyeong-Jun, Lee, Hyosung, Swanson, Hollie, Kim, Kyung-Bo·2010·Molecular BioSystems

Abstract

Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations, a small molecule-based novel technology termed “PROteolysis TArgeting ChimeraS (PROTACs)” has been developed, targeting proteins for degradation at the post-translational level. Despite the promising potential of PROTACs to serve as molecular probes of complex signaling pathways, their design has not been generalized for broad application. Here, we present the first generalized approach for PROTAC design by fine-tuning the distance between the two participating partner proteins, the E3 ubiquitin ligase and the target protein. As such, we took a chemical approach to create estrogen receptor(ER)-α targeting PROTACs with varying linker lengths and the loss of the ER in cultured cells was monitored via western blot and fluorometric analyses. We found a significant effect of chain length on PROTAC efficacy, and, in this case, the optimum distance between the E3 recognition motif and the ligand was a 16 atom chain length. The information gathered from this experiment may offer a generalizable PROTAC design strategy to further the expansion of the PROTAC toolbox, opening new possibilities for the broad application of the PROTAC strategy in the study of multiple signaling pathways.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/c0mb00074d

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The linker can contribute to PROTAC solution conformation and degradation efficiency (DC50/Dmax), and influence E3 ligase-POI interactions and presentation of the POI within the zone of ubiquitylation.

    “The linker can contribute to the PROTAC solution conformation68 and degradation efficiency (DC50/Dmax)69, and influence the E3 ligase–POI interactions and presentation of the POI within the zone of ubiquitylation (Fig. 5).”

    From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [69]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [22]Zheng FF Kuduk SD Chiosis G Munster PN Sepp-Lorenzino L Danishefsky SJ Rosen N Cancer Res 2000 60 2090 2094 10786665

Cited by

Sorted by citations

Authors
Cyrus, K., Wehenkel, M., Choi, E.-Y., Han, H.-J., Lee, H., Swanson, H., & Kim, K.-B.
Affiliations
  • University of Kentucky (US)
  • Department of Pharmaceutical Sciences, University of Kentucky a , Lexington, Kentucky, 40536-0596, USA kbkim2@uky.edu +1 859 257 7564 +1 859 257 5301
Venue
Molecular BioSystems
Published
2010-10-04
Volume
7
Issue
2
Pages
359-364
ISSN
  • 1742-2051 (ISSN-L)
  • 1742-206X
OpenAlex
W2002111767
Cited by
232
References
26
Citations by year
2026: 27 · 2025: 39 · 2024: 36 · 2023: 23 · 2022: 36 · 2021: 24 · 2020: 18 · 2019: 9 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 1 · 2013: 1 · 2012: 2
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Molecular BioSystems (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Foundation for Pharmaceutical Education
  • National Institutes of Health
  • National Cancer Institute (R01CA131059, CA131059)
  • National Institute of Environmental Health Sciences (ES014849, R01ES014849)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
PROTACs, linker length, E3 ubiquitin ligase, estrogen receptor alpha, protein degradation, PROTAC design
MeSH terms
Humans, Hydrolysis, Proteins, Ubiquitin-Protein Ligases, Cell Line, Tumor, Estrogen Receptor alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review